Neoadjuvant Gemcitabine+nab-Paclitaxel for resectable and borderline resectable pancreatic cancer-feasibility study for the elderly

Neoadjuvant Gemcitabine+nab-Paclitaxel for resectable and borderline resectable pancreatic cancer-feasibility study for the elderly - GANAC-PE study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048555

Enrollment

Registered

2022-08-10

Start date

2022-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable and Borderline resectable pancreatic cancer

Interventions

Neoadjuvant chemotherapy Gemcitabine 1000mg/m2+nabPaclitaxel 125mg/m2 1/week for 3 weeks, 1-week rest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically proven resectable and borderline resectable pancreatic cancer

Exclusion criteria

Exclusion criteria: 1) Patients with active multiple cancer lesions 2) Patients with any history of serious allergic reaction 3) Patients with serious comorbidity (Infectious, respiratory, cardiac, kidney and liver diseases) 4) Patients who are judged as inappropriate research subjects

Design outcomes

Primary

Measure	Time frame
3-year recurrence-free survival 3-year overall survival	—

Secondary

Measure	Time frame
completion rate, adverse events and surgical outcomes, etc	—

Countries

Japan

Contacts

Public ContactHidehiro Sawa

Hyogo Prefectural Awaji Medical Center Surgery

hsawa.amc@gmail.com0799221200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026